Already a member? Become a member Register
PCSK9 Forum

rss LinkedIn News
rss LinkedIn Latest News Updates

17th International Symposium on Atherosclerosis

23-25 May 2015, Amsterdam, The Netherlands

PlayMaking premature CHD history

Making premature CHD history

Dr Samuel Gidding discusses how treating children with FH early can make premature CHD history

read more »
PlayHow to identify children with FH

How to identify children with FH

Dr Samuel Gidding discusses how to identify children with FH

read more »
PlaySafety of lowering LDL-C

Safety of lowering LDL-C

Dr Albert Wiegman discusses the safety of lowering LDL C in FH children

read more »
PlayEAS Consensus Panel on Paediatric FH

EAS Consensus Panel on Paediatric FH

Dr Raul Santos discusses the EAS Consensus Panel statement on FH in children – Spanish Dr Raul Santos discusses the EAS Consensus Panel statement on FH in children – Portuguese

read more »
ISA 2015: Alirocumab treatment well accepted by patients and clinicians

ISA 2015: Alirocumab treatment well accepted by patients and clinicians

While injectable treatment is common among some specialities, this is not the case among clinicians managing patients with dyslipidaemia. PCSK9 monoclonal antibody, which is injected subcutaneously every 2 or 4 weeks, is undoubtedly effective in the management of high cardiovascular risk patients with elevated low-density…

read more »
ISA 2015: PCSK9 inhibitors effective in mixed dyslipidaemia

ISA 2015: PCSK9 inhibitors effective in mixed dyslipidaemia

Treatment with evolocumab or alirocumab was as effective in high risk patients with mixed dyslipidaemia, as in patients solely with elevated low-density lipoprotein (LDL) cholesterol, according to two reports at ISA 2015. Dr Kees Hovingh, Academic Medical Center, Amsterdam, the Netherlands discussed data from an…

read more »
PlayISA 2015: Evolocumab in TAUSSIG homozygous FH cohort

ISA 2015: Evolocumab in TAUSSIG homozygous FH cohort

News from one of the largest cohort of patients with homozygous familial hypercholesterolaemia (FH, inherited high cholesterol) in the TAUSSIG (Trial Assessing Long-Term Use of PCSK9 Inhibition in Subjects With Genetic LDL Disorders) study strengthens the data for evolocumab.1 In 100 patients with homozygous FH,…

read more »
PlayISA 2015: EAS Consensus Panel publishes Position Statement on Paediatric Familial Hypercholesterolaemia

ISA 2015: EAS Consensus Panel publishes Position Statement on Paediatric Familial Hypercholesterolaemia

The European Atherosclerosis Society (EAS) Consensus Panel has today published a new position paper aiming to raise awareness of the urgent need to identify and treat children with familial hypercholesterolaemia (FH) early. The EAS Consensus Panel position paper also provides clinical guidance for the diagnosis…

read more »